Mindi Lemonds
Nurse Practitioner · Saint George, UTNPI 1306560818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,423 of the $6,346 with a category attached, or 85.5%. 39 manufacturers reported payments, led by Boston Scientific at 24.6% of the total. 2025 is the largest year on record at $2,630, 2.4 times the $1,110 reported in 2023. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AbbVie$937
- Novartis$537
- Biogen$427
- Pfizer$299
- Argenx US, Inc.$251
- plus $2K from 33 others
What the payments were for
- Travel & lodging$82013%
- Food & beverage$5,42385%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $1,562 |
| AbbVie | 57 | $937 |
| Novartis | 18 | $537 |
| Biogen | 21 | $427 |
| Pfizer | 14 | $299 |
| Argenx US, Inc. | 10 | $251 |
| Johnson & Johnson | 6 | $225 |
| Lundbeck LLC | 11 | $213 |
| EMD Serono, Inc. | 13 | $200 |
| ANI Pharmaceuticals, Inc. | 9 | $193 |
| AstraZeneca(2 entities) | 8 | $174 |
| Merz Pharmaceuticals, LLC | 3 | $128 |
| UCB, Inc. | 6 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Genentech USA, Inc. | 6 | $104 |
| Acadia Pharmaceuticals Inc | 6 | $94 |
| Neurocrine Biosciences, Inc. | 5 | $78 |
| Amgen | 2 | $75 |
| Lilly USA, LLC | 4 | $68 |
| Tanabe Pharma America, Inc. | 3 | $59 |
| Bristol Myers Squibb | 3 | $52 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| CSL Behring | 3 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| SPR Therapeutics, Inc | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Banner Life Sciences, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Insightec,inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,346 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 30 | $31,556 |
| QuliptaAtogepant | 27 | $29,781 |
| Emgality PenGalcanezumab-Gnlm | 40 | $29,264 |
| UbrelvyUbrogepant | 23 | $25,553 |
| Glatiramer Acetate | 12 | $21,615 |
| RexultiBrexpiprazole | 13 | $19,764 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $16,483 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $14,132 |
| Primidone | 151 | $5,140 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 189 | $4,640 |
| Gabapentin | 167 | $3,188 |
| Lacosamide | 39 | $2,962 |
| Levetiracetam | 107 | $2,555 |
| Pyridostigmine Bromide | 19 | $2,293 |
| AmantadineAmantadine Hcl | 37 | $2,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $937 | $55,33450 claims |
| PfizerNurtec Odt | $299 | $31,55630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $19,76413 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $49 | $2,29319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Saint George
- Jenna SummerhaysSaint George$6K
- Mikala LarsenSaint George$4K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.